At Yale School of Medicine in New Haven, researchers have upended the economic calculus of sickle cell disease treatment, finding that stem cell transplantation — not the newly approved gene therapy — offers the most cost-effective path to lifelong remission for adults. The finding, published in Blood, is the first direct comparison of all three major treatment approaches, and it carries implications for how health systems worldwide allocate resources for a disease affecting nearly 8 million people globally.
The discovery matters because sickle cell disease remains a relentless health burden, particularly for people with ancestral ties to regions where malaria is endemic — sub-Saharan Africa, the Indian subcontinent, the Arabian Peninsula, and parts of the Mediterranean. About 100,000 individuals in the United States live with the disorder, characterized by misshapen blood cells that lodge in vessels, blocking blood flow and triggering organ damage, severe infections, and crippling pain episodes. Until recently, standard care meant managing symptoms with hydroxyurea, pain medication, and transfusions — never truly curing the disease.
Gene therapy, approved by the FDA in 2023 for patients 12 and older, promised a breakthrough. It uses intensive conditioning followed by infusion of a patient's own genetically modified stem cells capable of producing normal blood. But breakthrough comes at a cost: the research led by Dr. George Goshua, assistant professor of medicine in medical oncology and hematology at Yale, found that gene therapy's price would need to drop 66 to 71 percent to match the cost-effectiveness of stem cell transplantation. "Gene therapy is an incredible immune innovation, but it comes with an astronomical cost," Goshua said.
The alternative gaining ground is non-myeloablative haploidentical allogeneic stem cell transplantation — a refined approach that uses less chemotherapy and radiation to prepare the bone marrow than traditional transplants, making it far less toxic. Crucially, it requires only a half-matched donor instead of a full match, dramatically expanding access for sickle cell patients who often struggle to find compatible donors. While graft-versus-host disease — a serious complication where the immune system attacks donor cells — remains a risk, rates have improved substantially.
The researchers used a decision-analytic model projecting outcomes for adults 18 and older, comparing all three options head-to-head. The evidence suggests that recent prospective studies confirm stem cell transplantation is now safer and more effective than in previous decades, yet cost-effectiveness data in the gene therapy era had been sparse until now.
Dr. Goshua emphasizes this should not become a blanket denial of gene therapy coverage. "From a patient perspective, there are multiple trade-offs across sickle cell treatment options, including differences in eligibility, timing, and a patient's individual values and preferences," he said. "That said, it is important for individuals living with sickle cell disease to have access to as many treatments as possible; gene therapy may be the best option for many patients." Treating physicians must continue offering patients all available options through shared decision-making.
For policymakers, however, the analysis offers clarity: understanding the cost-effectiveness of these treatments can equip governments to make informed, strategic decisions about investing in sickle cell care. As health systems worldwide grapple with rising treatment costs, this research suggests that expanding access to improved stem cell transplantation — particularly the less toxic, half-matched donor approach — may deliver both better outcomes and better value.